Schond Greenway

Schond Greenway

No más puestos en curso
54 años
Health Technology
Consumer Services
Finance

Perfil

Schond L.
Greenway
worked at Halozyme Therapeutics, Inc. as Executive Director-Strategy & IR from 2013 to 2016.
Worked at Mesoblast Ltd. as VP & Global Head-Investor Relations from 2016 to 2021.
Worked at Avalo Therapeutics, Inc. as Chief Financial Officer & Treasurer from 2021 to 2022.
Worked at Definium Therapeutics, Inc. as Chief Financial Officer from 2022 to 2024.
Also held positions at DURECT Corp.
as VP-Investor Relations & Strategic Planning and at Barclays Capital, Inc. as Vice President-Healthcare.
Education includes undergraduate studies at Florida A&M University and an MBA from the University of Virginia Darden School of Business.

Antiguos cargos conocidos de Schond Greenway.

EmpresasCargoFin
DEFINIUM THERAPEUTICS, INC. Director Financiero/CFO 03/05/2024
AVALO THERAPEUTICS, INC. Director Financiero/CFO 14/02/2022
MESOBLAST LIMITED Contacto de Relaciones con Inversores 01/02/2021
HALOZYME THERAPEUTICS, INC. Contacto de Relaciones con Inversores 01/01/2016
DURECT Public Communications Contact -
Ver el detalle de la experiencia de Schond Greenway.

Formación de Schond Greenway.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

54

Relaciones de 1er grado

8

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas8

Health Technology

Health Technology

Finance

Consumer Services

Health Technology

Health Technology

Consumer Services

Health Technology